High Content Screening – Emerging importance of novel reagents/probes and pathway analysis By Dr John Comley The number of high content screens will increase by 50% over the coming year; signal pathway analysis was seen as the most relevant high content screening (HCS) application; with greatest interest in… Read More
Redefining Drug Discovery Informatics By Bryan S. Koontz As the pharmaceutical industry changes in response to unprecedented challenges, information technology supporting the drug discovery process must evolve and be redefined in order to improve research productivity and success rates. Improvements to traditional computational… Read More
Computer-aided design: progress towards more rational drug discovery By Dr Wolfgang H.B. Sauer Drug discovery is a science, a craft and an art, and often it requires a fair amount of serendipity or plain luck to succeed. Success is rare and costly, as evidenced by numerous reports and… Read More
By Dr Y. Douglas Dolginow The art and science of prediction is a risky and humiliating exercise. As bad as we are at it, predicting things remains one of the fundamental human instincts, undoubtedly linked to a Darwinian selective advantage for our species. Read More
How a new compliance agenda is changing the face of the drug discovery industry By Dr Doug Dean and Frances Bruttin Safe and effective drug products for the 21st century can be developed if, and only if, firms understand the mechanism of action of their products, and they… Read More
Exposure response modelling a safe and profitable way to speed drugs to market By Dr Gregory Fisher and Dr Arthur L. Craigmill The applicability of physiologically-based pharmacokinetic modelling (PBPK) far exceeds that of classical PK in predictive pharmacokinetics, tissue dosimetry, drug efficacy, and drug safety. This in… Read More
The search for validated biomarkers in the face of biosystems complexity By Professor Ian Humphery-Smith and Will Dracup As the pharmaceutical industry is all too well aware, the genomics and postgenomic sciences have delivered an excessive number of drug targets few of which have been well validated. Read More
The Impact of RNAi on Drug Discovery By Dr Christopher P. Miller RNAi (RNA interference) is an important target validation tool that has risen to prominence since 2001. For a number of reasons, it has supplanted other pre-existing target validation tools and is now the method of choice… Read More
Overview of biomarkers in disease, drug discovery and development By Professor Stephen Naylor The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency. The parallels between the problems of producing new therapeutic agents and… Read More
Patent Pools as a Solution to the licensing problems of diagnostic genetics – United States and European perspectives By Dr Jorge A. Goldstein, Dr Ted J. Ebersole, Marvin C. Guthrie, Annette A. Hirschfeld and Bart J. van den Broek Advances in diagnostic genetic testing have resulted in the… Read More
The Use and Usefulness of Transgenic Systems in the Discovery of New Medicines By Professor Jan Tornell The pharmaceutical industry is faced with the challenge to deliver truly novel medicines to a market under financial pressure when pharmaceutical R&D becomes increasingly difficult and complex. Read More
Experimental Medicine – Developing biomarkers in early discovery to bridge preclinical and clinical development By Dr Robert Dix In today’s pharmaceutical research and development environment a major problem is the transition of too many drugs to later stages of development with insufficient and/or inadequate information (eg efficacy, dosing),… Read More
Systems biology, information, disease and drug discovery By Professor Stephen Naylor Pharmaceutical companies are confronted with an urgent need to increase their lead compound and clinical candidate portfolios and to satisfy market demands for continued innovation and revenue growth. The lack of improved… Read More
By Dr Ashok R Dongre, Dr Douglas Robinson, Dr Mark E Curran and Dr Nicholas C Dracopoli Molecular profiling is becoming increasingly important as a tool for the discovery and implementation of novel biomarkers for use in drug development. Modern profiling methods permit comprehensive analysis of… Read More
GENE EXPRESSION as a toxicological screening tool By Dr Bruce Seligmann The use of microarray data in drug development and requirements for FDA audit and approval. Toxicological safety testing of compounds has not yet advanced to the point where measurement of gene expression… Read More
The impact of early ADME profiling on drug discovery and development strategy By Dr Jianling Wang and Dr Laszlo Urban The increased costs in the discovery and development of new drugs, due in part to the high attrition rate of drug candidates in development, has led to… Read More